Organoid-guided Personalized Treatment of Pleural Effusion

NCT06959173 · tracked via the Priya Life Science China tracker

Sponsor

Henan Cancer Hospital

Phase

Observational

Started

2025-02-21

Last updated

2025-05-06

Condition(s) studied

Lung Cancer

Study summary

The study is a single-arm, single-center clinical research that utilizes patient-derived tumor organoids to predict drug sensitivity, thereby assisting clinicians in formulating treatment plans to benefit lung cancer patients with pleural effusion.

This study is divided into three parts: acquisition of clinical samples from patients, in vitro organoid culture and drug sensitivity testing, and correlation of organoid sensitivity results with clinical medication guidance. Researchers obtained pre-treatment tissue samples and provided them to Suzhou Xianjue Biotechnology Co., Ltd. to establish organoid models. Once established, drug incubation was performed for sensitivity testing. Subsequently, treatment for malignant pleural effusion was guided based on drug sensitivity data.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: (1)18 years of age and above; (2) Understand and voluntarily sign the informed consent form (ICF), and have good compliance, and can cooperate with diagnosis and follow-up; (3)ECOG score 0-2; (4) Accompanied by malignant pleural effusion; Presence of at least one measurable lesion as assessed by the investigator; Exclusion Criteria: 1. A history of malignant tumor in the past 5 years; 2. Complicated with serious complications, such as uncontrolled heart disease, severe arrhythmia requiring medical treatment, persistent watery diarrhea, etc.; 3. Pregnant or lactating female patients; Patients deemed unsuitable for participation in this study.

Primary outcome measure(s)

Objective Response Rate (ORR) — up to 12 months
Evaluation of therapeutic efficacy for pleural effusion: Objective Response Rate (ORR)

Trial sites (1)

Facility	City	Region	Status
Henan cancer hospital	Zhengzhou	Henan	Recruiting

More Henan Cancer Hospital trials in China

Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer Recruiting

Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases Recruiting

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. Recruiting

SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma Active, not recruiting

RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors Recruiting

Other trials for the same condition

Research on Early Screening and Diagnosis of Pulmonary Nodules Based on Novel Non-invasive Technologies. Recruiting

Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy Recruiting

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer Recruiting

Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer Recruiting

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06959173 on ClinicalTrials.gov ↗ ← All trials in China